Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors
NCT06132503
·
clinicaltrials.gov ↗
PHASE1
Phase
RECRUITING
Status
110
Enrollment
INDUSTRY
Sponsor class
Conditions
Relapsed or Refractory Lymphomas
Advanced Solid Tumor
Interventions
DRUG:
LP-284
Sponsor
Lantern Pharma Inc.